Toxic drugs, toxic system: Sociologist predicts drug disastersAugust 04, 2008Study says harm from prescription drugs growing, cites fatal flaws in drug testing, approval and marketing BOSTON - Americans are likely to be exposed to unacceptable side effects of FDA-approved drugs such as Vioxx in the future because of fatal flaws in the way new drugs are tested and marketed, according to research to be presented today at the annual meeting of the American Sociological Association (ASA). "Drug disasters are literally built into the current system of drug testing and approvals in the United States," said Donald Light, the sociologist who authored the study and a professor of comparative health policy at the University of Medicine and Dentistry of New Jersey. "Recent changes in the system have only increased the proportion of new drugs with serious risks."
According to a 1999 report for the Institute of Medicine, adverse drug reactions (ADRs) are the fourth leading cause of death in the United States and more than two million serious reactions occur every year. ADRs can occur for a number of reasons, including improper prescribed dosage, drug abuse and drug interactions. Light's analysis identifies the organizational foundations of patient risk from prescription drugs and suggests institutional reforms to help avoid or reduce future drug disasters. According to Light, rather than using current approved drugs as benchmarks of efficacy, the existing testing system evaluates the effectiveness of new drugs based on their effects compared to placebos. Systematic reviews indicate that one in seven new drugs is superior to existing drugs, but two in every seven new drugs result in side effects serious enough for action by the U.S. Food and Drug Administration (FDA), including black box warnings, adverse reaction warnings, or even withdrawal of the drug. Based on this system, Light asserts that new drugs are twice as likely to harm patients as to provide them with benefits superior to existing drugs. Light's analysis suggests another flaw lies within the design of clinical trials. He contends that pharmaceutical companies frequently design their trails to minimize evidence of toxic side effects. To do so, they sample from a healthier population atypical of patients who will actually take the drug, excluding people who are older, poorer or who have multiple health problems. Trials are run long enough to pick up main effects but not to detect some long term side effects. Approvals are based on these data; so drugs with harmful effects sometimes get through. "Based on our current system, the designation of 'safe and effective' on today's new drugs could be replaced with, 'apparently safe based on incomplete information, and more effective than a placebo,'" Light said. With regard to government oversight, Light cites serious under-funding of the FDA, which creates a dependency on the pharmaceutical industry-the industry FDA regulates-to pay its staff. In return for drug company funding, Light says, the industry expects faster reviews, but faster reviews potentially fail to identify serious long-term side effects. "Speed-up reviews for safety have more than tripled the number of 'black box warnings' of side effects or withdrawals after drugs are on the market," Light said. "Despite recent reforms to strengthen the FDA's role in protecting the public from harmful drugs, the harm-benefit ratio is worsening due to these reviews and relaxed rules that allow companies to promote drugs for unapproved uses." American Sociological Association | |||||||||||||||||||||
|
Related Side Effects Current Events and Side Effects News Articles Iressa proves just as effective as chemotherapy for lung cancer Gefitinib, also known as Iressa, the once-promising targeted therapy for the treatment of non-small cell lung cancer, has proven as effective as chemotherapy as a second-line therapy for the disease with far fewer side effects, according to an international Phase III clinical trial, led by researchers at The University of Texas M. D. Anderson Cancer Center. Systems biology brings hope of speeding up drug development Almost every day brings news of an apparent breakthrough against cancer, infectious diseases, or metabolic conditions like diabetes, but these rarely translate into effective therapies or drugs, and even if they do clinical development usually takes well over a decade. New platinum-phosphate compounds kill ovarian cancer cells A new class of compounds called phosphaplatins can effectively kill ovarian, testicular, head and neck cancer cells with potentially less toxicity than conventional drugs, according to a new study published this week in the journal Proceedings of the National Academy of Sciences. 2 new compounds show promise for eliminating breast cancer tumors Two new compounds created by a University of Central Florida professor show early promise for destroying breast cancer tumors. Pivotal Emory study focuses on teens at risk for psychosis Emory University in Atlanta is playing a key role in the largest, most comprehensive study ever funded by the National Institute of Mental Health (NIMH) of adolescents and young adults at risk for developing a psychotic disorder. MSU researcher studies ties between cholesterol drugs, muscle problems A Michigan State University researcher is studying whether the most popular class of cholesterol-lowering drugs may cause muscle problems in users. Purdue researcher invents molecule that stops SARS A Purdue University researcher has created a compound that prevents replication of the virus that causes SARS and could lead to a treatment for the disease. 3 clinical features identified to avoid misdiagnosis of TIAs For mini-strokes, or transient ischemic attacks (TIAs), both overdiagnosis and underdiagnosis can be perilous. Overdiagnosis neglects the real underlying illness. Underdiagnosis leaves a patient at risk of a full-fledged stroke. Both expose patients to erroneous therapies with potential side effects. No drop in IQ seen after bypass for child heart surgery The use of cardiopulmonary bypass does not cause short-term neurological problems in children and teenagers after surgery for less complex heart defects, according to pediatric researchers. First trial of gene therapy for advanced heart failure shows promising results Phase I results of the first clinical trial of gene therapy for patients with advanced heart failure show the approach to be promising, with improvements in several measures of the condition's severity. More Side Effects Current Events and Side Effects News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||